Our cutting-edge, evidence-based approach combines advanced, state-of-the-art medical technologies, treatment modalities, and research to provide our patients with optimal results in the treatment of dry eye disease, Meibomian gland dysfunction (MGD), blepharitis, and ocular rosacea
In the pivotal pharmacology work, absorption of the co-formulated tablet was estimated at roughly 0.41% of the dose and even that low figure required a specialized delivery system (see the next section)
Therefore, molecular characteristics determine delivery method suitability more than anything else
This kind of systemsbased approach is particularly important for patients who have plateaued on conventional diets or have complex conditions like prediabetes, fatty liver, or chronic fatigue